Company profile
Alector, Inc.
NASDAQ:ALECBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LATOZINEMAB | phase1_2 | — | 7 | active |
| Osugacestat | phase1 | — | 4 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03636204 | phase1 | completed | 2018-09-14 | 2019-12-31 | Alector Inc. | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation |
| NCT05744401 | phase2 | terminated | 2023-01-04 | 2025-01-31 | Alector Inc. | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease |
| NCT04111666 | phase1 | completed | 2019-12-14 | 2022-06-09 | Alector Inc. | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 |
| NCT05053035 | phase2 | terminated | 2021-09-02 | 2022-10-28 | Alector Inc. | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS |
| NCT04592874 | phase2 | completed | 2021-01-22 | 2024-08-19 | Alector Inc. | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease |
FDA applications (0)
No records yet.